What TJ Biopharma does

TJ Biopharma (天境生物), founded in 2016 and headquartered in Hangzhou, China, is a full-chain biotechnology company developing, manufacturing, and commercializing biologic therapies for autoimmune diseases, immuno-oncology, and metabolic diseases. The company operates an integrated value chain across a GMP-licensed manufacturing base in Hangzhou (drug manufacturing license Type A; capacity 3x2kL, expandable to 6x2kL), a discovery and translational R&D center in Shanghai, and clinical development and regulatory affairs in Beijing. Its core technology is the proprietary Antibody PLUS platform, which enables engineering of bispecific antibodies, trispecific antibodies, immunocytokines, and antibody-steroid conjugates and underpins a second-tier first-in-class innovation pipeline, while a first-tier pipeline of BLA-stage and Phase 3 assets provides near-term commercialization potential.

The company's pipeline includes felzartamab (CD38-directed antibody for multiple myeloma, IgA nephropathy, and primary membranous nephropathy; BLA submitted December 2024; FDA Breakthrough Therapy and Orphan Drug designations), eftansomatropin α (long-acting hGH for pediatric growth hormone deficiency; BLA December 2024), edagglutide α (long-acting GLP-1 for obesity and diabetes; BLA October 2025 and a second BLA June 2026), plonmarlimab (GM-CSF antibody; NMPA Breakthrough Therapy designation), ulileddimab (CD73 antibody for non-small cell lung cancer; NMPA Breakthrough Therapy designation), and givastomig (Claudin18.2 x 4-1BB bispecific for gastric cancer; FDA Orphan Drug designation).

TJ Biopharma monetizes its pipeline through a three-pillar revenue model: (1) strategic out-licensing of regional or global rights, exemplified by the April 2026 transaction with Biogen consolidating global rights to felzartamab for up to $850 million ($100 million upfront plus up to $750 million in milestones and royalties); (2) CDMO contract manufacturing services leveraging its Hangzhou GMP base; and (3) product commercialization royalties, including through partnerships such as the Shi Yao Ji Tuan (石药集团) collaboration for edagglutide α and CSPC for itaglutide alpha. The company is privately held with no public listing and operates primarily in mainland China, Hong Kong, and Taiwan, with global reach extended through partner-led commercialization.

Name

TJ Biopharma

Legal name

天境生物药业（杭州）股份有限公司

Website

https://tjbio.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

TJ Biopharma (天境生物) is a privately held Chinese full-chain biotechnology company that develops, manufactures, and commercializes biologic therapies for autoimmune diseases, immuno-oncology, and metabolic diseases, leveraging a proprietary Antibody PLUS discovery platform, integrated GMP manufacturing, and strategic licensing partnerships with global biopharma.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals (Biologic Therapies)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Biologic drug development
• Antibody therapeutics
• Immuno-oncology therapies
• Autoimmune disease treatments
• CDMO manufacturing services

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Core offering

TJ Biopharma is a full-chain biotechnology company that discovers, develops, manufactures, and commercializes biologic therapies targeting autoimmune diseases, oncology immunotherapy, and metabolic diseases. Its dual-tier pipeline includes BLA-stage and Phase 3 assets such as felzartamab, edagglutide α, and eftansomatropin α, as well as First-in-Class candidates built on the proprietary Antibody PLUS platform. Revenue is generated through out-licensing deals (e.g., the Biogen partnership), CDMO contract manufacturing services, and product commercialization royalties via regional partners such as CSPC.

Product overview

TJ Biopharma (天境生物) is a full-chain biotechnology company focused on autoimmune diseases, oncology immunotherapy, and metabolic diseases. The company operates a 'dual-tier' differentiated innovation pipeline: the first tier includes multiple BLA-stage and Phase 3 clinical products including felzartamab (CD38 for multiple myeloma/IgA nephropathy), eftansomatropin α (long-acting hGH), edagglutide α (long-acting GLP-1 for obesity/diabetes), plonmarlimab (GM-CSF for MAS/sHLH), uliledlimab (CD73 for NSCLC), and givastomig (Claudin18.2x4-1BB bispecific for gastric cancer). The second tier consists of First-in-Class innovations powered by the Antibody PLUS platform, including TJ-C64B, TJ-L1IF, TJ-MC203, TJ-TL23, TJ-RO4B, and TJ-AGC. The company has established a vertically integrated value chain from drug discovery through GMP manufacturing to commercial partnerships, generating revenue through licensing deals (e.g., Biogen partnership), CDMO contract manufacturing, and product commercialization royalties.

Differentiator

Problem solved

Functional benefit

Products and services

• Felzartamab (菲泽妥单抗) — CD38-directed antibody CD38-directed monoclonal antibody indicated for multiple myeloma, IgA nephropathy, primary membranous nephropathy, and antibody-mediated rejection; targets BLA and Phase 3 immunology indications.
• Eftansomatropin α (依坦生长激素α) — Long-acting human growth hormone (hGH) Long-acting hGH fusion protein indicated for pediatric growth hormone deficiency; China rights retained by TJ Biopharma.
• Edagglutide α (依达格鲁肽α) — Long-acting GLP-1 receptor agonist Long-acting GLP-1 receptor agonist indicated for obesity and diabetes; in partnership with CSPC Pharmaceutical Group for China commercialization.
• Plonmarlimab (普那利单抗) — GM-CSF antibody GM-CSF monoclonal antibody indicated for macrophage activation syndrome (MAS), secondary hemophagocytic lymphohistiocytosis (sHLH), gouty arthritis, and sepsis-associated macrophage activation syndrome; global rights retained.
• Uliledlimab (尤莱利单抗) — CD73 antibody CD73 monoclonal antibody indicated for non-small cell lung cancer in combination therapies (first-line dual and triple therapy); Greater China rights retained.
• Givastomig — Claudin18.2 x 4-1BB bispecific antibody Claudin18.2 x 4-1BB bispecific antibody indicated for gastric cancer; FDA Orphan Drug designation; licensed for Greater China region.
• Antibody PLUS Platform — Drug discovery platform Proprietary drug discovery platform powering TJ Biopharma's second-tier First-in-Class innovation pipeline, including bispecific antibodies, trispecific antibodies, immunocytokines, and antibody-steroid conjugates; underpins global-rights pipeline assets TJ-C64B, TJ-L1IF, TJ-MC203, TJ-TL23, TJ-RO4B, and TJ-AGC.
• CDMO Manufacturing Services Contract development and manufacturing organization services leveraging TJ Biopharma's Hangzhou GMP production base (drug manufacturing license Type A held; 3x2kL clinical and commercial supply capacity, expandable to 6x2kL). Supports the company's diversified revenue model.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Shi Yao Ji Tuan (石药集团)coreStrategic or Co-development Partner · 22 June 2026Partnership for itaglutide alpha (long-acting GLP-1) where Shi Yao Ji Tuan is the commercial partner. The second BLA for itaglutide alpha was accepted by China's NMPA in June 2026, following the first BLA acceptance in October 2025.
• BiogencoreStrategic or Co-development Partner · 20 April 2026Biogen acquired TJ Biopharma's exclusive rights to felzartamab (CD38-directed antibody) in Greater China for up to $850 million, including $100 million upfront and up to $750 million in milestone payments plus royalties. Transaction consolidates global rights under Biogen for late-stage immunology asset in Phase 3 trials for IgA nephropathy, primary membranous nephropathy, and antibody-mediated rejection.

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Hansoh Pharmaceutical: Chinese pharma with a diversified drug portfolio including biologics and antibody-based therapeutics across multiple therapeutic areas. Overlaps with TJ Biopharma in antibody modality and Chinese commercial focus.
• BeiGene: One of China's largest biotechs with a globally commercialized antibody portfolio (e.g., tislelizumab, Brukinsa) and broad oncology pipeline. Comparable in antibody development capability and global commercial footprint, though materially larger and more diversified.
• Hengrui Medicine: China's largest innovative pharma with broad biologics and small-molecule pipeline across autoimmune, oncology, and metabolic diseases. Comparable therapeutic breadth and biologics presence, though TJ Biopharma is far smaller and platform-focused.
• Wuxi Biologics: Global leader in biologics CDMO services with a large mammalian-cell manufacturing capacity. Comparable as a Chinese biologics operating platform with end-to-end discovery-to-manufacturing capability leveraged by TJ Biopharma through its CDMO service line.

Direct peers

• I-Mab Biopharma: China/US-listed biotech developing novel biologics (antibodies and bispecifics) for cancer and autoimmune diseases. Comparable in clinical-stage antibody portfolio and reliance on global outlicensing deals for value capture.
• Innovent Biologics: China-based biotech with an extensive antibody pipeline (PD-1, GLP-1, multiple bispecifics) spanning oncology, autoimmune and metabolic diseases. Directly comparable in target selection, antibody platform strategy, and dual China/global commercialization approach.
• Akeso Inc: Chinese biotech pioneering bispecific antibodies such as cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF), with a pipeline and clinical-development model closely resembling TJ Biopharma's Antibody PLUS platform-driven approach to first-in-class biologics.
• Junshi Biosciences: Chinese biotech with a multi-asset antibody pipeline including GLP-1 candidates, PD-1 antibodies, and bispecifics. Similar in therapeutic breadth across oncology and metabolic disease, and in partnering with multinational pharma for global development.
• RemeGen Co Ltd: China-based biotech commercializing antibody-drug conjugates (disitamab vedotin) and bispecific antibodies. Comparable in modality focus (antibody-based biologics), Chinese R&D base, and dual focus on oncology and autoimmune indications.
• Bio-Thera Solutions: Chinese biotech developing both novel monoclonal antibodies and biosimilars across oncology and autoimmune indications. Comparable therapeutic focus and antibody modality pipeline as TJ Biopharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tj-biopharma

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TJ Biopharma